전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved27 programs
AntibodyLimited DatastaleM.D. Anderson Cancer CenterPhase 1

LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide (LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide)

Metastatic Esophageal; Gastric Cancer · Metastatic Esophageal

#MetastaticEsophageal#Antibody#Phase1#monoclonal-antibody#GastricCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleM.D. Anderson Cancer CenterPhase 1

LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide (LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide)

Metastatic Esophageal; Gastric Cancer · Metastatic Esophageal

#MetastaticEsophageal#Antibody#Phase1#monoclonal-antibody#GastricCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleAIO-Studien-gGmbHPhase 2

trastuzumab (Herceptin, Post-operative treatment trastuzumab mono therapy)

Adenocarcinoma of the Gastroesophageal Junction; Adenocarcinoma of the Stomach · Adenocarcinoma of the Gastroesophageal J

#AdenocarcinomaoftheGastroesophag#Antibody#Phase2#monoclonal-antibody#AdenocarcinomaoftheStomach+1
Trials 1Status Active
AntibodyLimited DatastaleTriumvira Immunologics, Inc.Phase 2

pembrolizumab (Keytruda, TAC01-HER2 plus pembrolizumab)

HER2 Positive Gastric Cancer; Metastatic HER2 Positive Gastroesophageal Junction Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#HER2PositiveGastricCancer+2
Trials 1Status Discontinued
AntibodyLimited DatastaleRuijin HospitalPhase 2

Tirelizumab (Tirelizumab)

Esophageal Squamous Cell Carcinoma · Esophageal Squamous Cell Carcinoma

#EsophagealSquamousCellCarcinoma#Antibody#Phase2#monoclonal-antibody#Ruijin
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

Tucidinostat (Tucidinostat, Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab, chidamide)

Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma · PD-1

#PD-1#Antibody#Phase2#monoclonal-antibody#EsophagealSquamousCellCancer+3
Trials 1Status Active
AntibodyLimited DatastaleFudan UniversityPhase 2

Vebrekotuzumab (Vebrekotuzumab)

Esophageal Squamous Cell Carcinoma · Esophageal Squamous Cell Carcinoma

#EsophagealSquamousCellCarcinoma#Antibody#Phase2#monoclonal-antibody#Fudan
Trials 1Status Recruiting

2 / 2 pages

← PreviousNext →